Pancreatic Ductal Adenocarcinoma Harboring Germline BRCA 2 Mutation, A Case Report and Review of The LiteratureLemstrova Radmila1, Melichar Bohuslav1, Mohelnikova-Duchonova Beatrice1,2*
- *Corresponding Author:
- Beatrice Mohelnikova-Duchonova
Department of Oncology, Palacky University Medical School and Teaching Hospital
IP Pavlova 6, Olomouc, Czech Republic
E-mail: [email protected]
Received date: April 14, 2017; Accepted date: April 26, 2017; Published date: May 08, 2017
Citation: Radmila L, Bohuslav M, Beatrice MD (2017) Pancreatic Ductal Adenocarcinoma Harboring Germline BRCA 2 Mutation, A Case Report and Review of The Literature. Pancreat Disord Ther 7:182. doi: 10.4172/2165-7092.1000182
Copyright: © 2017 Radmila L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Introduction: Despite recent advances in the diagnosis and treatment of pancreatic ductal adenocarcinoma (PDAC) the prognosis of this tumor remains dismal. It is estimated that 5-10% of all PDAC patients harbor a germline BRCA-1 or BRCA-2 mutation. There is some evidence that BRCA-mutated PDAC cases respond to chemotherapy regimens based on platinum derivate and cross linking agents. Case report: Here we present a case of metastatic PDAC in a 41-year-old BRCA2 germline mutation carrier. The patient had a favorable response to systemic treatment, including a partial response even to the third line cisplatin monotherapy administered with palliative intent. Discussion: PDAC associated with BRCA mutation represents a special disease entity. Platinum derivates and cross linking agents should be considered even in the advanced palliative setting in these patients.